F0697

J

Failure to Ensure Continuous and Effective Pain Management for Hospice Residents

Metropolis, Illinois Survey Completed on 03-27-2026

Penalty

No penalty information released

Summary

The deficiency involves the facility’s failure to provide effective pain management for three residents receiving pain control, including one hospice resident at end of life. One resident with multiple myeloma, pulmonary embolism, chronic pain, spinal stenosis, osteoporosis with pathological fractures, fibromyalgia, and other comorbidities was on hospice care with orders for a Fentanyl patch, scheduled oral Dilaudid every two hours, and PRN Hydrocodone for breakthrough pain. Her care plan called for evaluation of pain, monitoring for non-verbal indicators, and assessing the effectiveness of pain interventions every shift. Despite this, the facility allowed her oral Dilaudid supply to be depleted and did not ensure timely replacement, resulting in a period of approximately six hours without the ordered narcotic while she was actively dying.

Family members reported that on the day in question the resident was in severe, uncontrolled pain, thrashing and crawling in bed, attempting to get out of bed, and requiring family to hold her to prevent falls. Multiple family members stated that the facility could not get her Dilaudid all day, that they repeatedly called hospice and even a hospital seeking help, and that the resident suffered intensely until medication finally arrived later in the afternoon. The hospice RN had identified the day before that the Dilaudid supply would not last, sent refill orders to the facility’s pharmacy before noon, and instructed facility staff to notify hospice if the medication was not delivered so alternate arrangements could be made. The hospice RN reported she never received such a call and only learned the medication was depleted after the last partial dose was given around 10:00 a.m. Facility nurses confirmed that the last dose from the bottle was given that morning, that no additional Dilaudid was available in the building, and that they relied on hospice to locate an open pharmacy and bring replacement medication, which did not arrive until mid- to late afternoon.

During the period without Dilaudid, staff documented that the resident’s scheduled doses at noon and 2:00 p.m. were not given and coded as “other/see progress notes,” while the resident exhibited restlessness, grimacing, and agitation as described by CNAs and family. An agency LPN caring for the resident stated she considered sending the resident to the emergency room for pain relief but did not do so, and another nurse reported that the facility’s pharmacy did not make Sunday deliveries. The primary physician/medical director stated he was not notified that the resident was out of Dilaudid or that her pain had increased. The facility’s own pain management policy required recognition of behavioral signs of pain and review of the MAR to determine the effectiveness and frequency of pain medication use, but the resident’s MDS documented no receipt of scheduled or PRN pain medications or non-medication interventions despite concurrent documentation that she was receiving an opioid.

Two additional hospice residents with pain needs also did not receive adequate pain assessment and management. One resident with multiple sclerosis, contractures, and other serious conditions was on a scheduled Norco regimen three times daily and had PRN Dilaudid ordered for moderate to severe pain and dyspnea. He reported that he was always in pain, that staff did not routinely ask him about pain, and that he had to request medication himself, sometimes forgetting until his pain became severe. His MAR showed all scheduled Norco doses documented with a pain level of 0 over multiple days and no use of PRN Dilaudid during the review period, while a hospice CNA stated she always asked him about pain and that he consistently reported being in pain.

Another hospice resident with Parkinson’s disease, severe dementia, heart failure, and other diagnoses had orders for scheduled Oxycodone four times daily and PRN Hydromorphone every four hours. His care plan required monitoring and recording pain characteristics every shift and observing for non-verbal signs of pain such as changes in breathing, facial expressions, and vocalizations. However, his MAR documented pain scores of 0 on all shifts over several weeks and no administration of PRN Hydromorphone. A hospice CNA reported that this resident complained of pain at times and that she had to notify the nurses. During observation, the resident was seen flinching in his legs, grimacing, gritting his teeth, and trying to adjust his feet, yet he was unable to answer questions, indicating reliance on staff to recognize and respond to non-verbal pain behaviors that were not reflected in the recorded pain assessments.